PD-L1 Testing: A Critical Step for Your Patients With Metastatic Triple-Negative Breast Cancer

Determining PD-L1 status can identify patients who are eligible for TECENTRIQ + nab-paclitaxel (nab-pac) 2

  • Metastatic TNBC has historically been an area of serious unmet need, with limited targeted therapy options 5,6

PD-L1 expression on tumor-infiltrating immune cells (IC) as a biomarker for TECENTRIQ in metastatic triple-negative breast cancer (mTNBC) 2

  • Tumor and immune cells in the tumor microenvironment both play an important role in immune evasion and tumor progression 7
  • PD-L1 expression on IC is a key player in regulating anticancer immunity and can predict response to cancer immunotherapy 8
  • IMpassion130 PFS results in the PD-L1+ population led to the accelerated approval of TECENTRIQ + nab-pac in PD-L1+ mTNBC 2
    • 41% of patients in the trial were PD-L1+ (n=369/902), defined as PD-L1–stained IC of any intensity covering ≥1% of the tumor area*

PD-L1 expression on IC with the VENTANA PD-L1 (SP142) Assay

PD-L1=programmed death-ligand 1.
*As determined by the VENTANA PD-L1 (SP142) Assay.

Test for PD-L1 to identify patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC

  • VENTANA PD-L1 (SP142) is the first and only FDA-approved assay for mTNBC, designed to stain PD-L1 on IC 9-11
  • Talk to your pathologists about adding PD-L1 to the biomarker panel for mTNBC, so that your patients are automatically tested
  • Select labs or diagnostic centers can also perform PD-L1 testing using SP142, the FDA-approved companion diagnostic for TECENTRIQ in mTNBC